Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
07:34am, Monday, 08'th Aug 2022
Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.
Pfizer reaches $5.4B deal for Global Blood Therapeutics
07:25am, Monday, 08'th Aug 2022
The New York drugmaker is buying Global Blood Therapeutics, which sells a drug for sickle-cell disease and has two in development. It will pay $68.50 per share.
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
07:05am, Monday, 08'th Aug 2022 Benzinga
Gainers
Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results.
Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6
Pfizer Inc. PFE, -1.18% has agreed to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer wi
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
06:48am, Monday, 08'th Aug 2022
Pfizer Inc said on Monday it has agreed to buy blood disorder drugmaker Global Blood Therapeutics in a $5.4 billion deal, as it looks to fortify its product pipeline.
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
06:45am, Monday, 08'th Aug 2022
NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive ag
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ
06:37am, Monday, 08'th Aug 2022
Pfizer Inc. PFE, -1.18% has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal reported, citing people familiar with the matt
Why Global Blood Therapeutics Stock Is Vaulting Higher Today
05:35pm, Friday, 05'th Aug 2022 The Motley Fool
Pfizer emerges as the lead suitor for the rare-disease company.
Why Global Blood Therapeutics Stock Is Vaulting Higher Today
01:35pm, Friday, 05'th Aug 2022
Pfizer emerges as the lead suitor for the rare-disease company.
Pfizer in Talks to Buy Global Blood Therapeutics: Report
12:08pm, Friday, 05'th Aug 2022
Pfizer is in talks to acquire Global Blood Therapeutics, which sells a treatment for sickle cell disease called Oxbryta, The Wall Street Journal reports.
WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion
11:58am, Friday, 05'th Aug 2022
Shares of Global Blood Therapeutics Inc. GBT, +48.47% jumped 9.5% in trading on Friday after The Wall Street Journal reported that Pfizer Inc. PFE, -0.49% is considering buying the company for about $
Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?
11:53am, Friday, 05'th Aug 2022 Zacks Investment Research
Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
11:44am, Friday, 05'th Aug 2022
Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
10:12am, Friday, 05'th Aug 2022 Benzinga
Gainers
ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per sh
Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?
09:02am, Friday, 05'th Aug 2022
Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
